News

Ophthalmologists graded AI bots' answers to questions from patients following cataract surgery

OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease, which affects approximately 100,000 people in the United States and Europe combined.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

How retina specialists are approaching treatment of GA in clinic.

The US Food and Drug Administration issued designations for the allogeneic cell therapy candidate, a therapeutic for corneal oedema

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

According to the company, AURN001 is the first allogeneic cell therapy to receive both FDA designations for the treatment of corneal edema secondary to corneal endothelial disease.

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

Investigators looked to see if a large language model could provide safe, accurate, and readable information to patient inquiries about cataract surgery.

Sustainability, artificial intelligence and economic considerations are hot topics at this year’s meeting

According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.

This Los Angeles-based ophthalmologist and medical creator discusses the role of social media in combating misinformation and building health care practices.

The Type A meeting addressed questions the FDA had about the late-stage product candidate

Proactive communication and leveraging advanced, yet reliable, technologies  to maximize efficiency are essential pillars of success.

We stand on the cusp of a new era in vitreoretinal surgery, one that has been marked by only a select few seminal innovations

Three approaches to examination provide a comprehensive overview

The retrospective real-world evaluation of the drug considered several important as-yet-unanswered questions

A key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

XLRP often leads to blindness by middle age with no treatment options currently available

To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.

Shift in the understanding of TED has led to a reevaluation of the Rundle curve

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss how isolated empty sella is not a sign of elevated ICP